- NZ$17.04m
- NZ$15.78m
- NZ$2.43m
Brief: Truscreen Places Additional 61.8 Mln New Ordinary Fully Paid Shares At NZ$0.02 Per Share
Brief: Truscreen Group Says Planning In Progress For Clinical Evaluation Trials In Indonesia & Kenya
Brief: Truscreen Group Says CEO Beata Edling Has Resigned
Brief: Truscreen Group Says Intention To Launch A One For Three Pro-Rata Renounceable Rights Issue
Brief: Truscreen Group Receives Approval In Mexico To Enter Public Health Sector
NZ's Truescreen hits over 5-month high on Mexican regulatory nod
Brief: Truscreen Group Says Included On Vietnamese Ministry Of Health Approved Technical List
Brief: Truscreen Says Vietnam As Key Market Is Expected To Contribute To Further Growth In H2
Brief: Truscreen Group Says Experienced Strong Sales Growth In Q1 FY24
NZ's Truscreen gains on receiving order from its China distributor
Brief: Truscreen Says To Launch One For Five Pro-Rata Renounceable Rights Issue
Brief: Truscreen Group Expects Market To Swiftly Return To Normal Trading
Brief: Truscreen Says HY Revenue In Line With Prior Half Year Ended 30 Sept
Brief: Truscreen Group Ltd Announces Appointment Of Beata Edling As Chief Executive Officer
BOD Australia falls on placement commitments, entitlement offer
New Zealand's Truescreen Group jumps on signing supply agreement with Zapco
Brief: Truscreen Group Says Signed 5-Year Manufacturing Deal For Supply Of Single Use Sensors
NZ's Truscreen gains after relaunch of cancer screening device in China
Brief: Truscreen Group Says Coga Trial Validates Superiority Of Truscreen Cervical Cancer Screening Method